global digital cash- Top Related searches

Zhengzhou plans to identify three 4A-level scenic spots. On December 12th, it was reported that through the procedures of "voluntary declaration, step-by-step recommendation, landscape review, on-site inspection and party group research", Zhengzhou Municipal Bureau of Culture, Radio, Film and Tourism plans to identify three scenic spots, including Zhongmu Zhengzhou Haichang Ocean Park, Gongyi Qinglong Mountain Ecological Tourism Zone and Guancheng Zhengzhou Shangdu Ancient City Tourist Zone, as national 4A-level tourist attractions. The publicity period is 5 working days from December 9.An earthquake with a magnitude of 5.6 occurred in the sea area northeast of Fiji. According to the measurement of the European and Mediterranean Earthquake Center, at 13: 51 local time on December 12th, a magnitude of 5.6 earthquake occurred in the sea area 478 kilometers northeast of Suva, Fiji (15.201 degrees south latitude and 178.282 degrees west longitude) with a focal depth of 10 kilometers.Nearly 40% of the skilled talents in Shenzhen exceed 4 million, and the total number of skilled talents in Shenzhen now reaches 4.033 million, and the proportion of skilled talents has increased to 38.5%. The team size and the proportion of skilled talents are among the highest in the country ... From the launching ceremony of the 4th Shenzhen Craftsman Week and the summary meeting of skilled talents in 2024 held recently, it was learned that the construction of high-skilled talents in Shenzhen achieved positive results in 2024, which became an important foundation for supporting Shenzhen's manufacturing and Shenzhen's innovation. (Shenzhen Special Zone Daily)

The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.Baijiayun received $15 million in financing. One-stop AI video technology service provider Baijiayun (NASDAQ：RTC) announced that the company had signed a series of important agreements with YA II PN, Ltd, a fund managed by Yorkville Advisors Global and LP. The company received $15 million in financing, and the down payment of $3 million was received on the signing date of the agreement.Genting Xinyao: The first prescription of itramod in Macau, China officially benefited Asian patients. Genting Xinyao announced that its first prescription of itramod was made in Jinghu Hospital in Macau, China on December 11th, which was the first prescription made by itramod after it was approved in Genting Xinyao Asia Authorized Zone, marking that this heavy product in the field of autoimmune diseases officially began to benefit Asian patients. Luo Yongqing, CEO of Genting Xinyao, said that the arrival of the first prescription of Ithmod in China and Macau was another milestone in the commercialization of Genting Xinyao. By 2030, the number of patients with ulcerative colitis in China is expected to more than double that in 2019, reaching about 1 million. There is a huge unmet demand for innovative therapies. Following the approval in Macau in April this year, Iturmod, as the third commercial new drug of Genting Xinyao, will bring new treatment options to more patients with ulcerative colitis.

Genting Xinyao: The first prescription of itramod in Macau, China officially benefited Asian patients. Genting Xinyao announced that its first prescription of itramod was made in Jinghu Hospital in Macau, China on December 11th, which was the first prescription made by itramod after it was approved in Genting Xinyao Asia Authorized Zone, marking that this heavy product in the field of autoimmune diseases officially began to benefit Asian patients. Luo Yongqing, CEO of Genting Xinyao, said that the arrival of the first prescription of Ithmod in China and Macau was another milestone in the commercialization of Genting Xinyao. By 2030, the number of patients with ulcerative colitis in China is expected to more than double that in 2019, reaching about 1 million. There is a huge unmet demand for innovative therapies. Following the approval in Macau in April this year, Iturmod, as the third commercial new drug of Genting Xinyao, will bring new treatment options to more patients with ulcerative colitis.The Nikkei 225 index closed at 39,881.10 points in early trading, up 1.29%.Consumer stocks in Hong Kong stocks fluctuated higher, with the same journey rising by more than 6%, Mengniu Dairy rising by more than 4%, and China Resources Beer, Master Kong Holdings and Haidilao rising.